New York, May 21, 2026, 08:05 EDT
- Aimei Health received a Nasdaq deficiency notice after missing the May 15 deadline for its March-quarter Form 10-Q, a quarterly financial report filed with the SEC.
- AFJK was quoted around $42.18 before the regular U.S. session; Nasdaq was still in pre-market trading at the dateline time.
- The company has 60 days from the May 19 notice to file the report or submit a compliance plan, with a possible 180-day window from the original due date if Nasdaq accepts the plan.
Aimei Health Technology Co., Ltd shares head into Thursday’s U.S. session with a fresh Nasdaq compliance problem after the blank-check company disclosed it had not filed its March-quarter report on time.
The issue matters now because AFJK is not an operating healthcare stock in the usual sense. It is a blank-check company, or listed shell, formed to buy or merge with another business, so listing status, deal timing and available trust cash can carry more weight than ordinary revenue trends.
Aimei said Nasdaq notified it on May 19 that the company was out of compliance with Listing Rule 5250(c)(1), which requires listed companies to file periodic financial reports on time. The late filing was the Form 10-Q for the quarter ended March 31, due May 15. The notice has no immediate effect on trading, but the company said failure to regain compliance could lead to delisting.
The stock’s early price action gave little clean signal. Investing.com showed AFJK at $42.18, with a last pre-market price of $42.00 on just 10 shares, a thin print that can make small orders look larger than they are. The same data showed a 52-week range of $6.75 to $130.37, underscoring how far the shares have swung.
Regular U.S. trading had not yet opened. Nasdaq’s normal day begins with a pre-market session from 4:00 a.m. to 9:30 a.m. ET, followed by regular trading from 9:30 a.m. to 4:00 p.m. ET. The exchange’s 2026 holiday calendar lists the next U.S. closure as Memorial Day on May 25, not Thursday.
The late quarterly report adds to a compliance run that began in April, when Aimei disclosed a separate Nasdaq notice over its delayed 2025 annual report. That earlier 10-K was due March 31, and the company filed a late-filing notice on April 1.
Aimei’s broader story is still the proposed business combination with United Hydrogen Group Inc. In its annual report, Aimei said shareholders approved the United Hydrogen transaction in November 2025 and that the related registration statement had been declared effective, but completion remained subject to conditions including Chinese regulatory review.
The clock is tight. On May 6, Aimei said $34,330.96 had been deposited into its trust account to extend its deadline to complete an initial business combination by one month, to June 6. The deposit was funded equally by its sponsor and United Hydrogen through a non-interest-bearing promissory note.
The company’s 2025 annual report showed why the filing delay matters to investors. Aimei had not begun operations as of Dec. 31 and said it would not generate operating revenue until after completing a business combination. Its auditor also flagged substantial doubt about its ability to continue as a going concern if it fails to complete a deal in the required time.
Peer context is uneven. Google Finance listed other blank-check names including Rising Dragon Acquisition, GigCapital7 and Hall Chadwick Acquisition among related stocks, with mixed moves rather than a single sector trend. For AFJK, the immediate trade is more about the filing cure period and the United Hydrogen deadline than a broad SPAC rally or selloff.
But the risk cuts both ways. A quick 10-Q filing, or a Nasdaq-accepted plan, could remove the near-term listing overhang. A longer delay, a rejected plan or another slip in the United Hydrogen timetable would leave holders exposed to a delisting process, another extension fight or, in the worst case, liquidation mechanics rather than operating-company growth.
